Immune response induced in Vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines

Journal of Clinical Immunology

Volumn 24, Issue 1, 2004, Pages 86-96

  Arroyo, J Carlos ^a,b   Gabilondo, Fernando ^b   Llorente, Luis ^b   Meraz Ríos, Marco A ^a   Sánchez Torres, Carmen ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cancer immunotherapy; Dendritic cell subsets; Immunological memory

Indexed keywords

CANCER VACCINE; CD14 ANTIGEN; CD16 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; PROSTAGLANDIN E2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANDIDA ALBICANS; CLINICAL ARTICLE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; FEVER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TRICHOPHYTON MENTAGROPHYTES; TUMOR IMMUNOLOGY; VACCINATION;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; DENDRITIC CELLS; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RECEPTORS, IGG;

EID: 1642283515     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000018067.71622.fb     Document Type: Article

References (33)

1. Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526, 2002
2. Yu Z, Restifo NP: Cancer vaccines: Progress reveals new complexities. J Clin Invest 110:289-294, 2002
3. Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC, Minasian L, Alpaugh RK, Weiner LM, Munn, DH: CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85:2910-2917, 1995
4. Ziegler-Heitbrock HWL: Heterogeneity of human blood monocytes: The CD14+CD16+ subpopulation. Immunol Today 17:424-428, 1996
5. - dendritic cells. Clin Immunol 100:325-338, 2001
6. +) subset of human monocytes preferentially become migratory dendritic cells in a model tissue setting. J Exp Med 196:517-527, 2002
7. Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sanchez-Schmitz G: CD16+ and CD16-human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 13:1571-1581, 2001
8. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002
9. McLaughlin JK, Lipworth L: Epidemiologic aspects of renal cell cancer. Semin Oncol 27:115-123, 2000
10. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163:408-417, 2000
11. Vogelzang NJ, Priest ER, Borden L: Spontaneous regression of his-tologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year follow up. J Urol 148:1247-1248, 1992
12. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F, Ernstoff MS : In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162:567-573, 1999
13. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group: N Engl J Med 338:1265-1271, 1998
14. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 6:332-336, 2000
15. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2:52-58, 1996
16. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
17. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJM, Jongmans W, Adema GJ, Debruyne FMJ, de Mulder PH, Oosterwijk E, Mulders PFA: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A phase I study. J Immunother 25:500-508, 2002
18. Kondo N, Inoue R, Kasahara K, Fukao T, Kaneko H, Tashita H, Teramoto T: Reduced expression of the interferon-gamma messenger RNA in IgG2 deficiency. Scand J Immunol 45:227-230, 1997
19. Ribeiro de Jesus A, Araujo I, Bacellar O, Magalhaes A, Pearce E, Harn D, Strand M, Carvalho EM: Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 68:2797-2803, 2000
20. Geissman F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19:71-82, 2003
21. Soares MM, Mehta V, Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555-6563, 2001
22. Levings MK, Sangregorio R, Roncarolo MG: Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295-1302, 2001
23. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June, CH: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276, 2002
24. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809-8814, 2001
25. Finke JH, Rayman P, George R, Tannenbaum CS, Kolenko V, Uzzo R, Novick AC, Bukowski RM: Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: Role of nuclear factor-kappaB suppression. Clin Cancer Res 7:940s-946s, 2001
26. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH, Thurnher M: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369-3376, 2002
27. Yi-qun Z, Joost van Neerven RJ, Kasran A, de Boer M, Ceuppens JL: Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Int Immunol 8:37-44, 1996
28. Waldrop SL, Davis KA, Maino VC, Picker LJ: Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 161:5284-5295, 1998
29. + T cells. J Immunol 164:265-272, 2000
30. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766-4772, 2001
31. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, Sallusto F: Memory and flexibility of cytokine gene expression as separable properties of human Th1 and Th2 lymphocytes. Nat Immunol 4:78-86, 2003
32. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells. Nat Immunol 1:311-316, 2000
33. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353-360, 1993